DDInter1534 DDInter1652
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Propafenone {u} (Compound) resembles {v} (Compound) Atomoxetine
Propafenone {u} (Compound) resembles {v} (Compound) Benazepril
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Propafenone {u} (Compound) binds {v} (Gene) CYP2C9
Propafenone {u} (Compound) upregulates {v} (Gene) KIAA0355
Propafenone {u} (Compound) downregulates {v} (Gene) IFRD2
Propafenone {u} (Compound) causes {v} (Side Effect) Lupus-like syndrome
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Propafenone (Compound) resembles Atomoxetine (Compound)
Propafenone (Compound) resembles Benazepril (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Propafenone (Compound) binds CYP2C9 (Gene)
Propafenone (Compound) upregulates KIAA0355 (Gene)
Propafenone (Compound) downregulates IFRD2 (Gene)
Propafenone (Compound) causes Lupus-like syndrome (Side Effect)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol